Jeff Yass’s Damora Therapeutics DMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-1,476
Closed -$93K – 12354
2023
Q2
$93K Buy
+1,476
New +$80.4K ﹤0.01% 11000
2023
Q1
– Sell
-412
Closed -$11.8K – 12912
2022
Q4
$11.8K Sell
412
-756
-65% -$31.4K ﹤0.01% 11906
2022
Q3
$55K Buy
+1,168
New +$59.2K ﹤0.01% 12133

Other funds holding DMRA

Jeff Yass's DMRA Position: Q3 2026 in Review

Jeff Yass reduced its Damora Therapeutics (DMRA) stake by 8.9% in Q3 2026, selling an estimated $30.2K and leaving 10,939 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #11573.

Jeff Yass first reported a position in DMRA in Q4 2021 and has held it in 12 quarters since. The position peaked at $312K in Q2 2026. 115 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.

  • Jeff Yass held 10,939 shares of Damora Therapeutics worth $233K as of Q3 2026.
  • Jeff Yass sold 1,070 Damora Therapeutics shares in Q3 2026, an estimated $30.2K.
  • Damora Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #11573 holding.
  • Jeff Yass first reported a position in Damora Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Jeff Yass's Damora Therapeutics position peaked at $312K in Q2 2026.
  • 115 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.